Background: Because of the varied presentation and associated high mortality the identification of patients with acute myocardial infarction is very critical for the patient management and has a bearing on the prognosis. Only about 22% patients admitted to cardiac care centers with chest pain having truly myocardial infarction. Aim: The goal of present study was to assess diagnostic value of serum ischemia modified albumin and compare it with sensitive cardiac troponin I and Creatine Kinase-MB in acute myocardial infarction. Methods: A diagnostic case control study was conducted on 102 patients presenting to the Emergency Department within 6 hrs of acute chest pain and 115 healthy age and sex matched volunteers formed the control group. Serum ischemia modified albumin level was estimated by albumin cobalt binding test using digital spectrophotometer, while troponin I was measured by immunofluroscence assay and creatine Kinase-MB was determined by immunoinhibition method. The sensitivity and specificity of ischemia modified albumin, troponin I and creatine kinase-MB for detection of acute myocardial infarction were analyzed. The results of ischemia modified albumin, troponin I and creatine kinase-MB alone and in combination were correlated. Results: Ischemia modified albumin (p<0.05) and troponin I (p<0.001) concentrations were significantly higher in acute myocardial infarction than healthy controls. Sensitivity, specificity, positive predictive value and negative predictive value of ischemia modified albumin for detection of acute myocardial infarction was 88.24%, 93.91%, 92.78% and 90.00% compared to 86.27%, 93.04%, 91.67% and 88.43% respectively for the troponin I and 78.43%, 100%, 100%, and 83.94% for creatine kinase-MB. Combined use of ischemia modified albumin, troponin I, creatine kinase-MB significantly enhanced the sensitivity to 96%. The area under the receiver operating characteristic curve of ischemia modified albumin in acute myocardial infarction was 0.90. Conclusion: Ischemia modified albumin is a new potential diagnostic biomarker used together with other gold standard cardiac biomarkers can improve early diagnosis of acute myocardial infarction.
Harsh Mohan, Textbook of pathology forward Ivan Danjanov.5th edition: 307-326.
Park K, Park’s Textbook of preventive and social medicine.18th edition: 286-290.
Vamadevan S, Ajay, Doraraj P, Prvalence. Indian J.Med.Res.2010; 132:561-566.
Plebani M. Biochemical markers of cardiac damage: from efficiency to effectiveness. Clin Clim. Acta . 2001; 311:3-7.
Graff L G, Dallara J, Ross M A.Impact on the care of the emergency department chest pain patient from the chest pain evalution registry (EHPER) study. AM.J.Cardiol, 1997; 80:563-569
Kritsanee M, Titiporn M,Saowanee L,Tomon T,Sarawut K.combinational determination of ischemia modified albumin and protein carbonyl in the diagnosis of nonST-elevation Myocardial Infarction. Indian journal of clinical biochemistry.2011 online published on 19 th February 2011.
Chawla R, Navendu G, Rajneesh C, Shweta Goyal. Ischemia Modified Albumin: A novel marker for acute coronary syndrome. Indian Journal of Clinical Biochemistry.2006; 21(1):77-82.
Shaoquing Ju,Juan Ni,Jianyou Su,Min Pan,Jianhua Z. Ischemia modified albumin is increased in patients with unstable angina : a new potential diagnostic biomarker of this acute coronary syndrome? Science. 2008; 39(11):668-670.
Bhagwan N, Ernest M, Rios P, Yang J, et.al. Evolution of human serum albumin cobalt binding assay for the assessment of myocardial ischemia and myocardial infarction. Clin.Chem.49:581-585.
Bar-Or D, Lau E, Winker J.A novel assay for cobalt-albumin binding and it,s potential as a marker formyocardial ischemia-a preliminary report. J Emerg Med. 2000;19:311-15.
online published on www.gmi-inc.com/Tosoh-AIA-360 -Immunoassay Analyzer. html # product _ desc
Young D.S. Eff. Drug. Clin. Lab. (1995)
IFCC methods for the measurement of catalytic concentration of enzymes, JIFCC. 1989 1: 130.
Ojha, S.K., Nandave,M., Arora, S., Narang, R., Dinda, A.K., and Arya, D.S., “Chronic administration of Tribulus terrestris Linn. Extract improves cardiac function and attenuatesmyocardial infarction in rats”. Int. J. Pharmacol., 2008;4: 1-10.
Kasap,S., Gonenc, A., Sener, D.E., and Hisar, I. “Serum Cardiac Markers in Patients with Acute Myocardial Infarction: Oxidative Stress, C-Reactive Protein and N-Terminal Probrain Natriuretic Peptide”. J Clin Biochem Nutr. 2007; 41(1): 50-57.
Arom KV,Flavin TF,Emery WR,Kshettry VR,Janey PA,Petersen RJ: Safety and efficacy of off-pump coronary artery bypass grafting.Ann.Thorac Surg.2000;69:704-710.
Kent Lewandrowski,Ahchean Chen,James Januzzi.Cardiac Markers for Myocardial Infarction A brief Review.Am J Clin Pathol.2002;118(1):S93-S99.
Sinha MK, Roy D, Gaze D, Collinson P, Kaski J. Role of IMA a new biochemical marker of myocardial Ischemia in the early diagnosis of acute coronary syndrome. Emerg. Med. J. 2004; 21: 29-34.
Nayak A, Rajpal K, Dinesh K, Purohit H, Taori G, Daginawala H . Prognostic Significance of Ischemia Modified Albumin in acute Ischemic stroke patients: A preliminary study. Annals of Neurosciences. 2011; 18 (1).
Eftihia S,Panagiota G. and Vassilis V. Ischemia modified albumin as an acute-phase reactant. Europian journal of cardiovascular medicine.2011;1(3):81-83.
Peacock F, Morris D, Anwaruddin S, Christenson R, Collinson P ,Goodware S. Meta-analysis of Ischemia Modified Albumin to rule out acute coronary syndromes in the emergency deparment. Am Heart J. 2006; 152:253-262.
Cui L, Zhang J, Wu Yonghua and Hu Xiaozhou. Assay of ischemia-modified albumin and C-reactive protein bfor early diagnosis of acute coronary syndromes. Journal of Clinical Laboratory Analysis.2008; 22: 45-49.
Mothes E, Faller P. Evidence that the principal coII binding site in human serum albumin is not at the N terminus: implication on the albumin cobalt binding test for detecting myocardial ischemia. Biochemistry. 2007; 46:2267-74.
Lawrence A. Kaplan, Amadeo J. Pesce, Steven C. Kazmierczak, Clinical Chemistry Theory, Analysis, Correlation, Forth edition: 567-579, 1059-1063.
kurt Baehmaier,Johannes Mair,Felix Offner,Christ.ian pummerer,Nikolaus Nau.Serum cardiac troponinT and Creatine Kinase-MB elevation in murine autoimmune myocarditis. Circulation.1995; 92:1927-1932
Aiki kaul,Rishi Sethi and Mithilesh K. Misra.Erythrocyte adenosine deaminase in post myocardial infarction angina patients. Indian journal of clinical biochemistry.2009;24(1):49-51.
Till K, Tanja Z,Dirk P, Ewa C. et al. Sensitive Troponin I assay in early diagnosis of acute myocardial infarction. The New England Journal of Medicine.2009; 361(9):868-877.
Carlos A.David R,Catherine J,Douglas P,Philip K,Harold H. Cardaic-specific Troponin I levels risk of coronary artery disease an graft failure following heart transplantation.JAMA.2000;284:457-464.
Takshid M, Kojuri, Tabei B, Tavasouli A, Heidary S, Tabanbeh M . Early Diagnosis of acute coronary syndrome with Sensitive Troponin I & Ischemia Modified Albumin. Iranian Cardiovascular research Journa.l 2010; 4(4): 144-151.
Saif A,James LJ,Aaron LB,Elizabeth LL,Kent BL. Ischemia –modified albumin improves the usefulness of standard cardiac biomarkers for the diagnosis of myocardial ischemia in the emergency department setting.Am J Clin Pathol 2005;123:140-145.
Collinson P, Gaze D, Bainbridge K,et al . Utility of admission cardiac Troponin and Ischemia modified albumin measurements for rapid evalution and rule out of suspwcted acute myocardial infarction in the emergency department. Emerg Med J. 2006; 23:256-261.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Copyright (c) 2020 Array